장마감
로그인 회원가입
RGC
RGC
Regencell Bioscience Holdings Ltd
7월 27일 4:00 PM ET (한국 7/28 05:00)
$5.83
+0.11 ▲ +1.92%
🌙 7월 27일 7:47 PM ET (한국 7/28 08:47)
$5.70
-0.13 ▼ -2.23%

레게셀 바이오사이언스 홀딩스(RGC) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$2.9B
스몰캡
P/E
-
배당수익률
없음
52주 위치
2%
저점 +29% · 고점 -92%
애널리스트
-
D
Fundamental health
vs. Drug Manufacturers - Specialty & Generic· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 66%
밸류에이션
데이터 부족
재무 안정
Top 58%
Index -P/E -EPS (ttm) -0.01Insider Own 88.68%Shs Outstand 494.5MPerf Week 14.31%
Market Cap 2.89BForward P/E -EPS next Y -Insider Trans -Shs Float 56.1MPerf Month -22.16%
Enterprise Value 2.89BPEG -EPS next Q -Inst Own 0.13%Short Float 1.66%Perf Quarter -78.79%
Income -0.01BP/S -EPS this Y -Inst Trans 11.56%Short Ratio 3.34Perf Half Y -81.44%
Sales 0.00BP/B 2360.32EPS next 5Y -ROA -134.35%Short Interest 0.93MPerf YTD -72.24%
Book/sh 0P/C 1223.99EPS past 3/5Y 22.39% -33.47%ROE -177.66%52W High -91.55% ($69.00)Perf Year -61.26%
Cash/sh 0P/FCF -Sales past 3/5Y -ROIC -523.06%52W Low 29.27% ($4.51)Perf 3Y 1169.57%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -71.08%Gross Margin -Volatility(W/M) 11.66% 18.89%Perf 5Y 2361.56%
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 1.15Perf 10Y -
Dividend Ex-Date -Quick Ratio 1.42EPS Q/Q -189.19%Profit Margin -RSI (14) 33.82Recom -
Dividend Gr. 3/5Y -Current Ratio 1.42Sales Q/Q -SMA20 -0.01% ($5.83)Beta 1.9Target Price -
Payout -Debt/Eq 0.32Earnings -SMA50 -59.61% ($14.43)Rel Volume 0.73Prev Close $5.72
Employees 10LT Debt/Eq 0.11EPS/Sales Surpr. -SMA200 -72.72% ($21.37)Avg Volume(3M) 0.28MPrice $5.83
IPO 2021/7/16Option/Short Yes/YesTrades 1336Volume 202,009Change 1.92%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Regencell Bioscience Holdings Ltd (RGC) Investment Analysis

What kind of company is Regencell Bioscience Holdings Ltd?

레게셀 바이오사이언스 홀딩스(RGC)
Healthcare · Drug Manufacturers - Specialty & Generic
#1830 by Market Cap — Mid-Cap

A Hong Kong-based biotech company that is in the early stages of researching treatment candidates for neurodevelopmental disorders such as ADHD (Attention Deficit Hyperactivity Disorder), built on a foundation of traditional herbal medicine.

Learn more about Regencell Bioscience Holdings Ltd →
Market Cap
$2.9B
Approx. KRW 4.0 trillion
⚖️ 1% of Samsung Electronics
Market Cap Rank1830
Employees10people
IPO2021/07/16
Current Price$5.83 ≈ 7,987원
NASD · Hong Kong

Key Events

예정된 이벤트가 없습니다

RGC의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.

  • 실적 발표는 보통 분기마다 있습니다
  • 배당주는 연 1~4회 배당락일이 있습니다
전체 경제/실적 캘린더 보기 →

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-177.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-134.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-523.1%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.32
✓ Healthy debt
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 0.36
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
1.42
✓ 평균
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 2.47
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.42
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 1.68
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Outlook data is insufficient

Analyst estimates and price targets have not been collected.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+22.4%
양호
My positionMid-range
Low range Average High range
미분류 중형주 Median 18.2% · Top 44%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-33.5%
부진
My positionBottom 25%
Low range Average High range
미분류 중형주 Median 6.4% · Bottom 12%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Outperformed the market by 2293%p over 5 years
RGC +2361.6% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
+2293.2%p
well ahead of the market
vs Health Care (XLV)
+2337.1%p
well ahead of the sector average
1-year basis
vs S&P 500
-77.3%p
Significantly behind the market
vs Health Care (XLV)
-81.0%p
Significantly behind the sector average
Rank among peers
5-year return Top among peers Based on 12 peers
1-year return Lowest among peers Based on 12 peers
Current position within 52-week range
Low (-29.3%p) High (-91.5%p)
Current price is 29.3% above the 52-week low and 91.5% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-85.8%
Annualized volatility
129.3%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-27
Uptrend zone

Current price $5.83 above the midline ($5.83). Normal upward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD -2.288 · Signal -2.963 · Hist 0.675. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 33.7 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 41.5.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Pricey
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
2360.32x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic median 1.55x · Bottom 1% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic

Who owns it?

Ownership flow is positive
Institutional net buying +11.6% · Short interest light 1.7% · Short interest up +0.5pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+11.6%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 0.1%
Retail-led
Healthcare 중형주 Median 89.4%
🧑‍💼 Insiders 88.7%
Founder/management large holders (strong skin-in-the-game)
Healthcare 중형주 Median 9.4%
👤 Retail investors (estimated) 11.2%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
1.7%
Low — limited short-side pressure
Healthcare 중형주 Median 11.3%
Past 90 days 📈 +0.5%p increase
Short interest days to cover
3.3 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 494.5M주
Float (tradable shares) 56.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding RGC

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
RGC RGC This Stock
$2.9B- 2360.3 -177.66% - +1.9%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 레게셀 바이오사이언스 홀딩스(RGC)?

레게셀 바이오사이언스 홀딩스(RGC) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of RGC?

The market cap of RGC is approximately $2.9B, ranking 1,830 within its sector.

What is the 52-week high and low for RGC?

RGC has recorded a 52-week high of $69.00 and a low of $4.51.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.